Prognostic potential of m7G-associated lncRNA signature in predicting bladder cancer response to immunotherapy and chemotherapy
Author:
Li Deng-xiong1, Wu Rui-cheng1, Wang Jie1, Feng De-chao1, Deng Shi1
Affiliation:
1. Department of Urology, Institute of Urology , West China Hospital, Sichuan University , Chengdu , China
Abstract
Abstract
Objectives
The influence of N7-methylguanosine (m7G) on cancer prognosis and immune response has been well-reported. However, the role of m7G-related long non-coding RNAs (lncRNAs) in bladder cancer (BC) remains largely unexplored. This study wanted to explore the relationship between m7G-related lncRNAs and BC.
Methods
To construct the m7G-related lncRNA signature, we utilized data obtained from TCGA. The collected data was then analyzed using R (version 4.2.1, Bell Laboratories, Boston, USA) and relevant packages.
Results
The m7G-related lncRNA signature consisted of seven lncRNAs (including GATA3-AS1, LINC00930, LINC01341, MED14OS, MIR100HG, RUSC1-AS1, SNHG4). The prognostic and clinical relevance of the risk score was corroborated in both the TCGA and IMvigor210 datasets. Individuals characterized by a high-risk score displayed substantial enrichment in pathways associated with immunity, notably those pertaining to the innate immune response, cytokine-mediated signaling pathways, and the adaptive immune system. Additionally, the high-risk score group showed a positive correlation with many immune checkpoints, including CD274, CD40, CTLA4, PDCD1, PDCD1LG2, among others. Moreover, a significant difference in the TCIA score was observed between the high-risk and low-risk score groups, indicating the potential distinct immunotherapy response rates. Furthermore, patients with a high-risk score demonstrated increased sensitivity to cisplatin, docetaxel, doxorubicin, gemcitabine, and vinblastine.
Conclusions
This m7G-related lncRNA signature demonstrates considerable promise as a prognostic biomarker in BC, facilitating the anticipation of responses to both immunotherapy and chemotherapy. This study provides a solid foundation for future investigations into the role of m7G-related lncRNAs in BC.
Publisher
Walter de Gruyter GmbH
Reference65 articles.
1. Sung, H, Ferlay, J, Siegel, RL, Laversanne, M, Soerjomataram, I, Jemal, A, et al.. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49. https://doi.org/10.3322/caac.21660. 2. Zi, H, He, SH, Leng, XY, Xu, XF, Huang, Q, Weng, H, et al.. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019. Mil Med Res 2021;8:60. https://doi.org/10.1186/s40779-021-00354-z. 3. Theodorescu, D, Li, Z, Li, X. Sex differences in bladder cancer: emerging data and call to action. Nat Rev Urol 2022;19:447–9. https://doi.org/10.1038/s41585-022-00591-4. 4. Shih, KW, Chen, WC, Chang, CH, Tai, TE, Wu, JC, Huang, AC, et al.. Non-muscular invasive bladder cancer: re-envisioning therapeutic journey from traditional to regenerative interventions. Aging Dis 2021;12:868–85. https://doi.org/10.14336/ad.2020.1109. 5. EAU Guidelines. edn. Presented at the EAU Annual Congress Milan 2023. Available from: EAU Guidelines Citing, Usage & Republication - Uroweb.
|
|